Background: Type 2 diabetes mellitus (T2DM) is associated with low-grade inflammatory response, which was reported to contribute to insulin resistance. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is widely used for glycemic control and has been suggested to exert anti-inflammatory effects.
Aims: to investigate the impact of sitagliptin on inflammatory biomarkers, glycemic control, and body measurements in patients with T2DM.
Materials and methods: The current prospective interventional study included 45 patients with T2DM who received sitagliptin (100 mg/day) for six months. Inflammatory biomarkers (TNF-α, IL-6, CRP, IL-10, and adiponectin) were measured using ELISA at pre- and post-treatment. Additional metabolic parameters, including fasting plasma glucose (FPG), HbA1c, and lipid profile (LDL-C, HDL-C, and triglycerides), were quantified on the Cobas® 4000, the clinical chemistry analyzer. Blood pressure and body mass index (BMI) were also recorded at both times. Comparative analysis was performed to assess biomarker changes.
Results: Sitagliptin treatment significantly reduced HbA1c (8.26% to 5.39%, p < 0.001) and FPG (164.86 to 127.88 mg/dL, p < 0.001). LDL-C and triglycerides also decreased significantly, while HDL-C showed a non-significant increase. TNF-α and CRP reduced inflammatory markers significantly after treatment (p < 0.001), whereas IL-6, IL-10, and adiponectin showed no significant changes. Regression analysis identified HbA1c (β = -0.75), FPG (β = -0.76), LDL-C (β = -0.36), triglycerides (β = -0.27), TNF-α (β = -0.46), and CRP (β = -0.42) as significant predictors of treatment response, while no significant associations for BMI, HDL-C, IL-6, IL-10, or adiponectin.
Conclusion: Our findings suggest that sitagliptin provide beneficial effects on glycemic control, lipid regulation, and related inflammatory responses, particularly through reductions in TNF-α and CRP, while its impact on other inflammatory markers remains limited.
ISSN-online 2360-2473 / ISSN-print 1223-0472
